Securities code: 002399 securities abbreviation: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) Announcement No.: 2022-003 Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected operating performance: \uf0f0 loss \uf0f0 turning loss into profit \uf0f0 rising in the same direction √ falling in the same direction
The same period of last year from January 1, 2021 to December 31, 2021
Profit attributable to listed companies: 275 million yuan – 41.25 million yuan
Net profit of shareholders: 1024 million yuan, down 73.14% – 59.72% over the same period of last year
Profit after deducting non recurring losses: 243 million yuan – 352.5 million yuan
Net profit after profit: 592 million yuan, down 58.95% – 40.46% over the same period of last year
Basic earnings per share: 0.1874 yuan / share – 0.2811 yuan / share earnings: 0.7568 yuan / share
2、 Performance forecast and pre audit
The relevant data of this performance forecast has not been pre audited by the accounting firm.
3、 Explanation of performance change reasons
1. During the reporting period, the company’s operating revenue achieved double-digit growth. Thanks to the sales force of enoxaparin preparation and enoxaparin API, the company’s heparin industry chain business revenue has achieved rapid growth; At the same time, based on the growth of orders on hand and the continuous and stable improvement of punctual and successful delivery rate, the company’s cdmo business revenue maintained a stable growth trend.
2. During the reporting period, the raw material cost of crude heparin was high, which had an impact on the gross profit margin of the company’s heparin industrial chain. In the second half of 2021, the price of raw materials showed a downward trend. The downward trend of raw material price of heparin crude products will be conducive to the performance of the company’s gross profit margin. However, due to the cyclical factors of production and sales, there is a certain time lag in the transmission of raw material purchase price to sales cost accounting.
3. During the reporting period, the net profit of the company was negatively affected by the sum of investment income and changes in fair value. In the same period of 2020, due to the investment income accounted and recognized by the associated company according to the equity method, the investment income formed by the sale of financial assets and dividends, and the increase in the fair value of kymab equity and other financial assets held by the associated company, The impact of the sum of investment income and changes in fair value on the current net profit is RMB 586 million; This data has a great impact on the year-on-year change of net profit in the reporting period.
Due to the investment income formed by the sale of financial assets and dividends, and the change of the fair value of financial assets held, the impact of non recurring profits and losses on the company’s net profit in 2021 was about 32 million yuan to 60 million yuan, while the impact of non recurring profits and losses on the net profit in the same period in 2020 was 432 million yuan, which had a certain impact on the year-on-year change of the company’s operating performance in 2021.
4、 Other relevant instructions
This performance forecast is the preliminary calculation result of the company’s financial department. Please refer to the company’s 2021 annual report for specific financial data. Please pay attention to investment risks.
Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) board of directors January 29, 2002
